Hypericin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Hypericin
- DrugBank Accession Number
- DB13014
- Background
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 504.4432
Monoisotopic: 504.084517488 - Chemical Formula
- C30H16O8
- Synonyms
- Hipericina
- Hypericin
- Hypéricine
- Hypericum red
- Hyperizin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlutathione S-transferase A1 Not Available Humans UGlutathione S-transferase P inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Hypericin. Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Hypericin. Acenocoumarol The risk or severity of adverse effects can be increased when Hypericin is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Hypericin. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Hypericin. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzopyrenes. These are organic compounds containing a benzene fused to a pyrene(benzo[def]phenanthrene) ring system.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Pyrenes
- Sub Class
- Benzopyrenes
- Direct Parent
- Benzopyrenes
- Alternative Parents
- Phenanthro-perylenequinones / Triphenylenes / Chrysenes / Phenanthrols / Anthracenes / Naphthols and derivatives / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Polyols / Organic oxides show 1 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-naphthol / 2-naphthol / Anthracene / Aromatic homopolycyclic compound / Benzo-a-pyrene / Benzo-e-pyrene / Chrysene / Hydrocarbon derivative / Organic oxide show 9 more
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- carbopolycyclic compound (CHEBI:5835) / Anthracenes and phenanthrenes, Anthrone type (C07606) / Anthracenes and phenanthrenes (LMPK13040001)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7V2F1075HD
- CAS number
- 548-04-9
- InChI Key
- BTXNYTINYBABQR-UHFFFAOYSA-N
- InChI
- InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36H,1-2H3
- IUPAC Name
- 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26}.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione
- SMILES
- CC1=C2C3=C(C)C=C(O)C4=C3C3=C5C2=C(C(O)=C1)C(=O)C1=C5C(=C(O)C=C1O)C1=C(O)C=C(O)C(C4=O)=C31
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0034271
- KEGG Compound
- C07606
- PubChem Compound
- 5281051
- PubChem Substance
- 347829150
- ChemSpider
- 4444511
- BindingDB
- 50060874
- 1546455
- ChEBI
- 5835
- ChEMBL
- CHEMBL286494
- ZINC
- ZINC000003780340
- Wikipedia
- Hypericin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Cutaneous T-Cell Lymphoma (CTCL) 1 somestatus stop reason just information to hide 3 Not Yet Recruiting Treatment Cutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) 1 somestatus stop reason just information to hide 2 Completed Other Cutaneous T-Cell Lymphoma/Mycosis Fungoides 1 somestatus stop reason just information to hide 2 Completed Treatment Cutaneous T-Cell Lymphoma/Mycosis Fungoides 1 somestatus stop reason just information to hide 2 Recruiting Treatment Cutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00732 mg/mL ALOGPS logP 3.92 ALOGPS logP 7.7 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) 6.03 Chemaxon pKa (Strongest Basic) -1.2 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 155.52 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 139.31 m3·mol-1 Chemaxon Polarizability 50.98 Å3 Chemaxon Number of Rings 8 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 227.4667179 predictedDarkChem Lite v0.1.0 [M-H]- 225.9317179 predictedDarkChem Lite v0.1.0 [M-H]- 225.9483179 predictedDarkChem Lite v0.1.0 [M-H]- 215.0333 predictedDeepCCS 1.0 (2019) [M+H]+ 227.1542179 predictedDarkChem Lite v0.1.0 [M+H]+ 225.8157179 predictedDarkChem Lite v0.1.0 [M+H]+ 225.9088179 predictedDarkChem Lite v0.1.0 [M+H]+ 217.19771 predictedDeepCCS 1.0 (2019) [M+Na]+ 226.9133179 predictedDarkChem Lite v0.1.0 [M+Na]+ 225.9997179 predictedDarkChem Lite v0.1.0 [M+Na]+ 225.2413179 predictedDarkChem Lite v0.1.0 [M+Na]+ 222.94563 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsGlutathione S-transferase A1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Glutathione S-transferase that catalyzes the nucleophilic attack of the sulfur atom of glutathione on the electrophilic groups of a wide range of exogenous and endogenous compounds (Probable). Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2) (PubMed:9084911). It also catalyzes the isomerization of D5-androstene-3,17-dione (AD) into D4-androstene-3,17-dione and may therefore play an important role in hormone biosynthesis (PubMed:11152686). Through its glutathione-dependent peroxidase activity toward the fatty acid hydroperoxide (13S)-hydroperoxy-(9Z,11E)-octadecadienoate/13-HPODE it is also involved in the metabolism of oxidized linoleic acid (PubMed:16624487)
- Specific Function
- fatty acid binding
- Gene Name
- GSTA1
- Uniprot ID
- P08263
- Uniprot Name
- Glutathione S-transferase A1
- Molecular Weight
- 25630.785 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
2. DetailsGlutathione S-transferase P
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2) (PubMed:9084911). Participates in the formation of novel hepoxilin regioisomers (PubMed:21046276). Negatively regulates CDK5 activity via p25/p35 translocation to prevent neurodegeneration
- Specific Function
- dinitrosyl-iron complex binding
- Gene Name
- GSTP1
- Uniprot ID
- P09211
- Uniprot Name
- Glutathione S-transferase P
- Molecular Weight
- 23355.625 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
- Dalmizrak O, Kulaksiz-Erkmen G, Ozer N: Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi. Protein J. 2012 Oct;31(7):544-9. doi: 10.1007/s10930-012-9433-6. [Article]
Carriers
1. DetailsAlbumin
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc (PubMed:19021548). Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity). Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity). Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli (PubMed:6234017). Does not prevent iron uptake by the bacterial siderophore aerobactin (PubMed:6234017)
- Specific Function
- antioxidant activity
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Albumin
- Molecular Weight
- 69365.94 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
Drug created at October 21, 2016 02:05 / Updated at May 05, 2022 15:33